New fixed dose chemical combinations

the way forward for better diabetes type II management?

Suhaj Abdulsalim, Munawar Peringadi Vayalil, Sonal Sekhar Miraj

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Diabetes type II is a complex disease with unclear pathophysiology. Lack of adherence and high cost of medicines invariably make the management of diabetes type II highly challenging. Newer fixed drug combinations (FDC) are cost effective and can improve the medication adherence thereby prevent the complications of diabetes. Safety and efficacy of newer FDCs are not well established in all populations. Moreover, extrapolating the efficacy and safety data globally may not be pragmatic. Our review will discuss newer chemical combinations available for the treatment of diabetes type II. Areas covered: In the present review, the authors discussed the newer FDCs available as add on therapy to the existing pharmacological interventions of diabetes type II that have shown promising results in various randomised trials with regard to efficacy and safety. Expert opinion: Safety and efficacy data of newer FDCs available as an adjuvant therapy to conventional pharmacological interventions in diabetes type II revealed that fewer new FDCs are promising with their high efficacy and low adverse effect. However, there is a need to explore the place in therapy to establish the utility of FDC in diabetes type II management.

Original languageEnglish
Pages (from-to)2207-2214
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume17
Issue number16
DOIs
Publication statusPublished - 01-11-2016

Fingerprint

Type 2 Diabetes Mellitus
Safety
Drug Combinations
Pharmacology
Drug Costs
Medication Adherence
Expert Testimony
Diabetes Complications
Therapeutics
Costs and Cost Analysis
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{33ef49a443ea4c4c8cb94fbe68b6853c,
title = "New fixed dose chemical combinations: the way forward for better diabetes type II management?",
abstract = "Introduction: Diabetes type II is a complex disease with unclear pathophysiology. Lack of adherence and high cost of medicines invariably make the management of diabetes type II highly challenging. Newer fixed drug combinations (FDC) are cost effective and can improve the medication adherence thereby prevent the complications of diabetes. Safety and efficacy of newer FDCs are not well established in all populations. Moreover, extrapolating the efficacy and safety data globally may not be pragmatic. Our review will discuss newer chemical combinations available for the treatment of diabetes type II. Areas covered: In the present review, the authors discussed the newer FDCs available as add on therapy to the existing pharmacological interventions of diabetes type II that have shown promising results in various randomised trials with regard to efficacy and safety. Expert opinion: Safety and efficacy data of newer FDCs available as an adjuvant therapy to conventional pharmacological interventions in diabetes type II revealed that fewer new FDCs are promising with their high efficacy and low adverse effect. However, there is a need to explore the place in therapy to establish the utility of FDC in diabetes type II management.",
author = "Suhaj Abdulsalim and {Peringadi Vayalil}, Munawar and Miraj, {Sonal Sekhar}",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/14656566.2016.1241235",
language = "English",
volume = "17",
pages = "2207--2214",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "16",

}

New fixed dose chemical combinations : the way forward for better diabetes type II management? / Abdulsalim, Suhaj; Peringadi Vayalil, Munawar; Miraj, Sonal Sekhar.

In: Expert Opinion on Pharmacotherapy, Vol. 17, No. 16, 01.11.2016, p. 2207-2214.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New fixed dose chemical combinations

T2 - the way forward for better diabetes type II management?

AU - Abdulsalim, Suhaj

AU - Peringadi Vayalil, Munawar

AU - Miraj, Sonal Sekhar

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Diabetes type II is a complex disease with unclear pathophysiology. Lack of adherence and high cost of medicines invariably make the management of diabetes type II highly challenging. Newer fixed drug combinations (FDC) are cost effective and can improve the medication adherence thereby prevent the complications of diabetes. Safety and efficacy of newer FDCs are not well established in all populations. Moreover, extrapolating the efficacy and safety data globally may not be pragmatic. Our review will discuss newer chemical combinations available for the treatment of diabetes type II. Areas covered: In the present review, the authors discussed the newer FDCs available as add on therapy to the existing pharmacological interventions of diabetes type II that have shown promising results in various randomised trials with regard to efficacy and safety. Expert opinion: Safety and efficacy data of newer FDCs available as an adjuvant therapy to conventional pharmacological interventions in diabetes type II revealed that fewer new FDCs are promising with their high efficacy and low adverse effect. However, there is a need to explore the place in therapy to establish the utility of FDC in diabetes type II management.

AB - Introduction: Diabetes type II is a complex disease with unclear pathophysiology. Lack of adherence and high cost of medicines invariably make the management of diabetes type II highly challenging. Newer fixed drug combinations (FDC) are cost effective and can improve the medication adherence thereby prevent the complications of diabetes. Safety and efficacy of newer FDCs are not well established in all populations. Moreover, extrapolating the efficacy and safety data globally may not be pragmatic. Our review will discuss newer chemical combinations available for the treatment of diabetes type II. Areas covered: In the present review, the authors discussed the newer FDCs available as add on therapy to the existing pharmacological interventions of diabetes type II that have shown promising results in various randomised trials with regard to efficacy and safety. Expert opinion: Safety and efficacy data of newer FDCs available as an adjuvant therapy to conventional pharmacological interventions in diabetes type II revealed that fewer new FDCs are promising with their high efficacy and low adverse effect. However, there is a need to explore the place in therapy to establish the utility of FDC in diabetes type II management.

UR - http://www.scopus.com/inward/record.url?scp=84992122555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992122555&partnerID=8YFLogxK

U2 - 10.1080/14656566.2016.1241235

DO - 10.1080/14656566.2016.1241235

M3 - Review article

VL - 17

SP - 2207

EP - 2214

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -